OptimizeRx Corporation (OPRX)

NASDAQ: OPRX · IEX Real-Time Price · USD
28.51
-0.04 (-0.12%)
Jun 29, 2022 12:45 PM EDT - Market open
-0.12%
Market Cap 517.43M
Revenue (ttm) 63.79M
Net Income (ttm) -2.75M
Shares Out 18.15M
EPS (ttm) -0.16
PE Ratio n/a
Forward PE 40.32
Dividend n/a
Ex-Dividend Date n/a
Volume 37,394
Open 28.36
Previous Close 28.54
Day's Range 27.69 - 28.71
52-Week Range 21.33 - 99.18
Beta 0.91
Analysts Buy
Price Target 60.44 (+112.0%)
Earnings Date Aug 3, 2022

About OPRX

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers, and patients. The company's products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems; and brand awareness and therapeutic support messaging services, such as brand awareness messages, reminder ads, and therapeutic support and unbrand... [Read more...]

Industry Health Care Technology
Employees 97
Stock Exchange NASDAQ
Ticker Symbol OPRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for OPRX stock is "Buy." The 12-month stock price forecast is 60.44, which is an increase of 112.03% from the latest price.

Price Target
$60.44
(112.03% upside)
Analyst Consensus: Buy
Stock Forecasts

News

OptimizeRx Corp. (OPRX) Moves 8.9% Higher: Will This Strength Last?

OptimizeRx Corp. (OPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price incre...

OptimizeRx Brings Real-World Evidence-Driven Engagement Programs to Social Media With New Exclusive Partnership

The latest omni-channel platform extension gives pharma access to up to 84% of prioritized HCPs on social media with content that is specific to their specialty The latest omni-channel platform extensio...

5 Small-Cap Stocks That Are Diamonds in the Rough

Small-cap stocks are less liquid, more volatile, and have a lower market cap. But they also offer the opportunity for greater returns.

Other symbols: COURFLYWNOVAPRTS

The 10 Best High-Growth Stocks to Buy

Except for energy stocks, 2022 has been a very difficult year to find any equities able to perform well in these volatile markets. And high-growth stocks have been hit especially hard.

OptimizeRx's Mike Rousselle Named One of 2022 PM360 ELITE 100

ROCHESTER, Mich., May 17, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy to...

OptimizeRx Authorizes $20 Million Share Repurchase Program

ROCHESTER, Mich., May 17, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, a...

OptimizeRx to Participate in Upcoming May Conferences

ROCHESTER, Mich., May 10, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, a...

3 Small-Caps That Might Be Acquisition Candidates

Here's why our roundtable thinks OptimizeRx, Affimed and Blueprint Medicines are all buys right now.

Other symbols: AFMDBPMC

OptimizeRx Corp. (OPRX) Reports Q1 Loss, Lags Revenue Estimates

OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of -200% and 0.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

OptimizeRx Reports First Quarter 2022 Financial Results, Revenue Up 22%, Successfully Completes EvinceMed Acquisition

ROCHESTER, Mich., May 04, 2022 (GLOBE NEWSWIRE) --  OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, ...

OptimizeRx Releases First Environmental, Social and Governance (ESG) Report

ROCHESTER, Mich., April 29, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy ...

Earnings Preview: OptimizeRx Corp. (OPRX) Q1 Earnings Expected to Decline

OptimizeRx Corp. (OPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

UPDATE – Surveyed Physicians Say Access Challenges Impact Their Care Plans for up to 33% of Patients

ROCHESTER, Mich., April 20, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy,...

1 in 3 Surveyed Physicians Say They Would Make a Different Treatment Choice If Medication Access Was Not a Factor

ROCHESTER, Mich., April 19, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy,...

Financial Times Ranks OptimizeRx Amongst Americas' Fastest-Growing Companies for the Third Consecutive Year

OptimizeRx grew 2021 revenue by 42% year-over-year, spotlighting the rapid growth from the convergence of technology and healthcare OptimizeRx grew 2021 revenue by 42% year-over-year, spotlighting the r...

OptimizeRx Acquires EvinceMed, a Specialty Drug Prescription Initiation Platform

OptimizeRx expands reach of its point-of-care solutions to simplify the prescribing process of specialty medications for healthcare providers, and to enable greater access for patients OptimizeRx expand...

OptimizeRx to Participate In-Person at 34th Annual ROTH Conference, March 13-15, 2022

ROCHESTER, Mich., March 07, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy ...

OptimizeRx Corp. (OPRX) Q4 Earnings and Revenues Beat Estimates

OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of 22.22% and 1.07%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

OptimizeRx Reports Fourth Quarter and Full Year 2021 Financial Results, Revenue Increased 42%, Demand from Large Phar...

ROCHESTER, Mich., Feb. 24, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, ...

OptimizeRx Corp. (OPRX) Reports Next Week: Wall Street Expects Earnings Growth

OptimizeRx Corp. (OPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OptimizeRx's Mike Rousselle Named to MM+M's 40 Under 40 List of the Medical Marketing Industry's Brightest Young Stars

ROCHESTER, Mich., Feb. 01, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, ...

3 Under-the-Radar COVID Stocks

Here's why our roundtable participants like NRx Pharmaceuticals, FIGS, and OptimizeRx.

Other symbols: FIGSNRXP

OptimizeRx's AI-Driven Therapy Initiation and Persistence Platform Wins 2022 BIG Innovation Award

Improving the continuum of patient care through enabling technology at point-of-care remains a core company-wide mission Improving the continuum of patient care through enabling technology at point-of-c...

OptimizeRx to Participate in Panel Presentation at LifeSci Partners Corporate Access Event 2022

Panel to take place January 6, 2022 at 8:30am ET

OptimizeRx's Evidence-Based Physician Engagement Solution Named One of the Most Innovative Products of the Year by PM360

The solution uses the Company's AI-driven Therapy Initiation and Persistence Platform to deliver tailored engagement leveraging real-world evidence insights in real-time The solution uses the Company's ...